Risk factors
Monte Rosa Therapeutics (GLUE) risk factors
Item 1A of every Monte Rosa Therapeutics, Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
87 risks, 4 new, 7 dropped, 14 reworded since the prior year. Pipeline expanded to include MRT-8102 alongside MRT-2359 and Novartis-partnered MRT-6160 moving to Phase 2.
Filed Mar 17, 2026 - FY2024 10-K risk factors
90 risks. Monte Rosa faces early-stage biotech risks centered on its QuEENTM discovery engine and pipeline candidates like MRT-2359 and MRT-6160. The company lacks commercial product revenue, has a history of operating losses, and relies heavily on sole-source suppliers and third-party contractors.
Filed Mar 20, 2025